HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

* Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis. * HSPA12B is primarily located in endothelial cells and detectable during sepsis. * The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sepsis Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital

Shanghai, 200433, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients
Patients meet the diagnostic criteria according to the grouping

Exclusion criteria

patients without informed consent
patients who were undergoing continuous renal replacement therapy before sampling
patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on

Treatment and study plan

Primary outcomes

28-day mortality

Time frame: 28 days

mortality within 28 days after recruitment.

Sponsors and collaborators

Lead sponsor

Changhai Hospital

Other

Registry information

Important dates

Study start: 2011
Primary completion: 2013
Study completion: 2013
First posted: May 6, 2013
Registry last updated: Nov 25, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed